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Abstract

CO-ADMINISTRATION OF SILDENAFIL POTENTIATES DOXORUBICIN-INDUCED
APOPTOSIS IN PROSTATE CANCER: THE ROLE OF NF-B

By Sarah H. Hassanieh, B.S.
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2008

Major Director: Rakesh C. Kukreja
Professor, Department of Internal Medicine, Division Cardiology

Our recent studies have shown that that erectile dysfunction (ED) drugs including
Sildenafil (Viagra), Vardenafil (Levitra) and Tadalafil (Cialis) enhance killing of several
types of cancer cells by anticancer drug, Doxorubicin (DOX). We observed increased cell
death by apoptosis in response to the combined treatment with ED drugs and DOX.
However, the mechanism of such enhancement of cell death by combined treatment of ED
drugs and DOX is not fully understood. Nuclear factor-B (NF-B) is an oxidant-sensitive
transcription factor that plays a critical role in the immediate-early activation of a multitude
of genes that have been documented to play critical role in programmed cell death
(apoptosis). NF-κB activation has been shown to block apoptosis and its inhibition
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improves existing anti-oncogenic therapy such as chemotherapy. In the present study, we
tested the hypothesis whether combined treatment of prostate cancer cells, PC3, with
Sildenafil plus DOX would attenuate the activation of NFB by inhibiting translocation of
the p65 and p50 subunits to the nucleus and by phosphorylation of cytosolic IB In
addition, we investigated the effect of DOX and DOX plus Sildenafil on the expression of
BCL family of proteins which play critical role in apoptosis. We treated PC3 cells with
1.5 μM DOX with or without 10 µM Sildenafil for 6 hours and 72 hours. The nuclear
translocation of p65 and p50 and expression of BCL family of proteins was determined by
western blot analysis. Our results show that combined treatment of DOX and Sildenafil
significantly reduced the nuclear translocation of p65 and p50 as compared with DOX
alone (P < 0.05). This correlated with the significant reduction in the expression of Bcl-2,
BclxL and phosphorylation of BAD. These data provide an important mechanism by which
Sildenafil treatment augments the apoptotic potential of DOX in PC3 cancer cells.

viii

Introduction

Prostate cancer
Prostate cancer is the most common solid tumor malignancy in men and the
second most deadly cancer in men of all ages in the United States (De Marzo et al. 2007).
One out of five men is at risk of developing prostate cancer during a lifetime course, and
1 in 33 will die (Jemal et al. 2007). Localized prostate cancer is initially treated with
curative intent by radiation therapy or surgery. If these treatment options fail or the
cancer metastasizes, the next step is androgen deprivation treatment by bilateral
orchiectomy, downregulating gonadotropin-releasing hormone (GnRH) receptors with
agonist and antagonist, or reducing the hypothalamic GnRH secretion by estrogen
administration (Damber and Aus. 2008). Androgen ablation reduces symptoms in about
70–80% of patients with advanced prostate cancer, but most tumors relapse within 2
years and progress to an androgen-independent phase. Patients with androgenindependent prostate cancer (AIPC) experience fatigue, increased bone pain, and a rise in
serum prostate specific antigen (PSA) (Fossa et al. 2002). No cure exists for AIPC, and it
is in dire need of new treatment strategies.
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Doxorubicin:
The anthracycline antibiotics continue to be the most effective cancer chemotherapeutic
agents ever since their discovery in 1960s. Doxorubicin (DOX) and Daunorubicin
(DNR) were the first two anthracyclines isolated from the actinobacteria Streptomyces
peucetius ATCC 29050. As shown in figure 1, DNR and DOX are derived from 1propionyl-CoA and 9-malonyl-CoA to produce a decaketide that is converted to
aklanonic acid (Jiang and Hutchinson. 2006). Next, aklanonic acid is converted to DNR
proceeding through the biosynthetical intermediates  rhodomycinone and rhodomycin
D. DOX is finally achieved by DNR hydroxylation at C-14 (Tang et al. 1996). Although
the structures DOX and DNR share a close homology to one another, they are used to
treat different cancers (Minotti et al. 2004). DNR is indicated in the treatment of acute
lymphoblastic or myeloblastic leukemias, while DOX has a broader spectrum activityused for the treatment of a variety solid tumors such as those of the breast, bile ducts,
endometrial tissue, the esophagus and liver, osteosarcomas, soft-tissue sarcomas and nonHodgkin’s lymphoma (Wiernik and Dutcher. 1992; Murphy GP. 1995). Despite their
efficiency as chemotherapeutic agents, they pose a threat to normal health tissues in the
form of congestive heart failure (CHF) and chronic cardiomyopathy. This sparked the
search for a better DOX resulting in about 2000 anthracycline analogues with only a few
earning clinical approval.
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Figure 1: Daunorubicin and Doxorubicin Biosynthesis in S. peucetius (Tang et al. 1996).

The most notorious analogues are Idarubicin (IDA) and Epirubicin (EPI) and can be
obtained from DNR and DOX, respectively by removal of the 4-methoxy group in ring D
from DNR and by an axial-to-equatorial epimerization of the hydroxyl group at C-4' in
daunosamine (sugar moiety displayed in the chair configuration in figure 2) of DOX.
Whether IDA and EPI are successful in alleviating the cardiomyopathies is unclear and
awaits further assessment; therefore, DOX and DNR remain to be the best
chemotherapeutic drugs ever developed.
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Figure 2: Chemical structures of DOX DNR EPI AND IDA anthracyclines. The side
chains (marked in grey) of DNR or IDA terminate with a methyl in place of a primary
alcohol compared with DOX or EPI. The dotted arrows point to the structural
modifications in EPI compared with DOX (axial-to-equatorial epimerization of the
hydroxyl group at C-4' in daunosamine), or in IDA compared with DNR (lack of the
methoxy group at C-4 in ring D) (Minotti et al. 2004).

Mechanisms of anthracyline cytotoxicity remain controversial. However, the possible
mechanisms include: 1) interference of macromolecular biosynthesis by DNA
intercalation; 2) generation of free radicals and lipid peroxidation; 3) DNA binding and
alkylation; 4) DNA cross-linking; 5) interference with DNA strand separation and DNA
helicase; 6) direct membrane effects; 7) induction of DNA damage through inhibition of
topoisomerase II; 8) apoptosis induction (Gewirtz. 1999). Of the most accepted
4

mechanisms that have been proven in a variety of cancer cell lines are the inhibition of
topoisomerase II and the free radical generation (Minotti et al. 1999).

Topoisomerases are enzymes that modify the structure of DNA, causing transient
single or double strand breaks that are subsequently repaired after changing the twisting
structure of the molecule. These enzymes are very important in cell division and
reproduction, as are the transcriptional activity that occurs during many cellular
processes. The anthracyclines act as topoisomerase II poisons by forming an irreversible
ternary complex (enzyme-DNA-anthracycline) instead of the physiological reversible
binary complex (enzyme-DNA) (Zucchi and Danesi. 2003). This ternary complex
causes DNA damage specifically, protein associated persistent (rather than transient)
strand breaks in DNA leading to apoptosis (Gewirtz. 1999; Zucchi and Danesi. 2003;
Sander and Hsieh. 1983).

DOX and other anthracyclines can also cause DNA damage generating reactive
oxygen species (ROS) and hydroxyl radicals (·OH) in a mechanism that involves one
electron redox cycling (figure 3) along with the release of low molecular weight iron
(Fe(II)) from intracellular stores (Minotti et al. 2004). Electrons are supplied from
NAD(P)H-oxidoreductases such as cytochrome P450 of the endoplasmic reticulum and
nuclear envelope and endothethial nitric oxide synthase to the quinone moiety in ring C
in DOX to form a semiquinone, which will regenerate into its parent quinone by reducing
molecular oxygen to ROS superoxide anion (·O2 -) and hydrogen peroxide (H2O2)
(Minotti et al. 1999; Vasquez-Vivar et al. 1997). In addition, the semiquinone can
5

oxidize the bond between ring A and daunosamine to form a 7-deoxyaglycone, which has
the ability to permeate the cell membrane and exert damaging effects by introducing
ROS.

Figure 3: One-electron redox cycling of anthracyclines (Minotti et al. 2004).

Moreover, the accompanied Fe(II) release from one electron cycling augments the
damaging effects, with the formation of 3:1 drug (DOX)-Fe(II) complexes that
decompose H2O2 using the available ·O2 - into highly reactive ·OHs (Minotti et al. 1999).
It has been suggested that the oxidative damage in tumor cells is attributed to
anthracyclines at supraclinical doses, while topoisomerase II inhibition prevails at doses
< 5M (Gewirtz. 1999). It is conceivable; however, that cumulative anthracycline
dosage overtime will introduce cardiac risk due to the formation of ROS in the
6

cardiomyocyte mitochondria (Myers. 1998). The build-up of ROS in cardiomyocytes
results in dissipation of mitochondrial membrane potential (m) and cytochrome c
release eventually leading to apoptosis (Childs et al. 2002).
In the clinical setting, DOX is administered intravenously with a usual dose of 60
mg/m2 every three weeks, with a dose limit of 450-550 mg/m2 (Minotti et al. 2004).
However, smaller, more frequent doses (once per week) are commonly used depending
on type of malignancy, overall chemotherapeutic regimen, prior history of anthracycline
exposure, and cardiac risk factors. Peak serum concentrations of DOX are reached
quickly following intravenous injection and fall by approximately 50% after thirty
minutes. However, significant levels persist for up to 20 hours. DOX is mainly
metabolized hepatically by reduction and hydrolysis of its ring substituents. The alcohol
metabolite of DOX, Doxorubicinol, is pharmacologically active, whereas the aglycone
derivative is inactive. Anthracyclines are mainly excreted in the bile with a small amount
excreted in the urine. Because, toxic metabolites are re-circulated in the process of
biliary excretion, dose reduction needs to be considered in patients with hepatic disease
or elevated hepatic transaminases (Minotti et al. 2004).

Doxorubicin-induced apoptosis in cardiac cells:
It is now recognized that apoptosis is the mechanism underlying Doxorubicin-induced
dilative cardiomyopathy and CHF. DOX has been shown to induce apoptosis in a variety
of cardiomyocyte cell lines through numerous receptor-mediated (extrinsic) and
mitochondrial (intrinsic) apoptotic pathways (Minotti et al. 2004). With respect to the
7

extrinsic apoptotic pathway, DOX strongly increased recombinant Fas ligand (rFasL)
apoptosis in neonatal rat cardiomyocytes, supported by an increase in caspase-8 activity
(Yamaoka et al. 2000). Fas ligand is a member of the TNF family of cytokines that when
binds to its receptor recruits Fadd (Fas receptor-associated death domain) protein leading
to activation of initiator caspases (eg, caspase-8) as shown in figure 4 (Kalyanaraman et
al. 2002). Caspase-8 will then cleave and activate effector caspases (eg, caspase-3),
which will degrade or activate cellular protein to eventually lead to cell death.
With respect to the intrinsic apoptotic pathway, it has been well-documented that
DOX upregulates Bax (pro-apoptotic protein), which triggers cytochrome c release by
facilitating mitochondrial channel opening (Wang et al. 1998b). This leads to the
formation of the apoptosome, which is a complex of apoptosis activating factor (Apaf-1),
cytochrome c, and pro-caspase-9 resulting in the cleavage and activation of caspase-9.
Furthermore, Bax homodimers can be associated with the mitochondria, and the have the
ability to directly activate caspase-3 and other potential apoptotic pathways (Reed. 1995).
Interestingly, Bax can be directly activated by p53, because it contains a p53 binding site.
It has been demonstrated that H2O2 and ‘O2 – generated from redox cycling of DOX can
activate p53 (Miyashita and Reed. 1995)
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Figure 4: Extrinsic and intrinsic Doxorubicin-induced apoptotic pathways in cardiac
cells (Kalyanaraman et al. 2002).

BCL-2 family proteins are pivotal players in the regulation of apoptosis that function to
either induced programmed cell death (pro-apoptotic) or promote cell survival (antiapoptotic). These proteins contain at least one of four conserved -helical BCL-2
homology domains (BH1, BH2, BH3, and BH4) (Gross et al. 1999). BCLxL and BCL-2
are survival proteins that contain all four domains. BAD, a BH3-only pro-apoptotic
protein is susceptible to phosphorylation two serine sites (Ser-112 and Ser-136), which
results in its inactivation (Zha et al. 1996). In its phosphorylated state, BAD is
sequestered by in the cytosol by the phosphoserine docking protein, 14-3-3 (Downward.
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1999). When it is dephosphorylated, it translocates to the mitochondria, where it can
form heterodimers with survival proteins BCL-2 or BCLxL, thereby inhibiting them
(Gross et al. 1999; Zha et al. 1996; Zhou et al. 2000). This promotes cell death by
leading to opening of mitochondrial permeability transition pore (MPTP) and release of
cytochrome c (Halestrap et al. 2000).
On the other end of the spectrum, survival proteins (eg. BCLxL and BCL-2),
which repress apoptosis, become down-regulated (Kalyanaraman et al. 2002). In a
normal cell, the mitochondrial membrane permeability is stabilized by the association of
BCL-2 homodimers (Reed. 1995). There is evidence that the protection of mitochondrial
permeability is lost due to the sequestration of BCL-2 homodimers by the formation of
BCL-2/Bax heterodimer (Herrmann et al. 1996). This action is attributed to H2O2
generated from redox cycling of DOX, again with evidence linking p53 to Bax activation
(Huang et al. 2000).

Phosphodiesterase-5 Inhibitors:
Cyclic guanosine monophosphate (cGMP) is an important regulator of wide variety of
physiological processes in many different tissues of the body (Rybalkin et al. 2003).
Smooth muscle relaxation is achieved when nitric oxide (NO) activates soluble guanylate
cyclase (sGC), an enzyme that converts guanosine triphosphate (GTP) to cyclic cGMP.
This results in the activation of cGMP-dependent protein kinase (PKG), which goes on to
phosphorylate proteins leading to a decrease in calcium influx (Das et al. 2008). This

10

process is brought to an end with the breakdown cGMP to GMP by phosphodiesterase-5
(PDE5). Inhibition of PDE5 activity allows the relaxation cycle to be prolonged and
enhanced (Rybalkin et al. 2003). Sildenafil citrate (Viagra) is a vasoactive drug that has
been used in the treatment of erectile dysfunction (ED) (Boolell et al. 1996). Sildenafil
works by inhibiting PDE5, leading to the accumulation of cGMP allowing vasodilatation
in the corpus cavernosum (Das et al. 2005).
Sildenafil can elicit its actions any place where there is PDE-5; therefore, it can
be used to treat problems other than ED. Our laboratory has demonstrated that Sildenafil
can induce cardioprotection through opening of mitochondrial KATP channels in rabbits, a
phenomenon known as preconditioning (Ockaili et al. 2002). Activation of PKG in the
cardiomyocytes leads to the opening of mitochondrial KATP channels, which partially
compensates for the loss in membrane potential (Kukreja et al. 2005). This allows
protons to be extruded, which forms an H+ electrochemical gradient for ATP synthesis
and Ca2+ transport. We have also shown that Sildenafil-induced cardioprotection occurs
by activation of Protein Kinase C (PKC) (Das et al. 2004).
NO has been recently shown to play a significant role in Sildenafil induced
cardiac preconditioning against apoptosis and necrosis in mice cardiomyocytes (Das et al.
2005). NO is synthesized from L-arginine by one of three isoforms of NO synthase
(NOS): endothethial (e), neuronal (n), and inducible (i) NOS (Moncada and Higgs. 1993;
Moncada et al. 1991). NO derived from eNOS constitutively expressed, releasing NO in
the nM range in response to intracellular Ca 2+ transients (Stefano et al. 2000). iNOS
functions in the cardiovascular and immune system and is highly regulated by cytokines
11

(Moncada and Higgs. 1993). NO serves as a heme ligand and is capable of binding the
heme iron of sGC leading to enhanced formation of cGMP (Denninger and Marletta.
1999). With regards to preconditioning with Sildenafil, an upregulation of both iNOS
and eNOS mRNA and protein expression promoting NO release offers a potent
cardioprotective effect against ischemia/reperfusion (I/R) injury (Das et al. 2005;
Salloum et al. 2003)

Prevention of Doxorubicin-Induced Cardiomyopathy with Sildenafil:
As discussed above, anti-cancer drugs (such as DOX) may cause severe cardiotoxicity
that ultimately lead to cardiomyopathy. The cardiotoxic effects of DOX continue to be
the major restraint in the current cancer chemotherapy. Our laboratory recently
demonstrated that in vivo treatment of mice with Sildenafil before administration of DOX
conferred protective effects against Doxorubicin-induced cardiotoxicity (Fisher et al.
2005). Sildenafil pretreatment attenuated myocyte apoptosis, maintained mitochondrial
membrane potential, preserved myofibrillar integrity, alleviated left ventricular
dysfunction and ST-segment prolongation. Similarly, in the isolated cardiomyocytes,
DOX treatment caused significant increase in apoptosis, caspase-3 activation, and
disruption of mitochondrial membrane potential, all of which were attenuated by
Sildenafil. In addition, the protective effects were abolished by either L-NAME (an
inhibitor of NOS) or 5-HD (a blocker of mitoKATP), indicating the participation of NO
and mitoKATP in mediating the protective effects of Sildenafil against Doxorubicininduced cardiomyopathy (Fisher et al. 2005). Interestingly, in a rat model of hypertensive
12

cardiomyopathy induced by chronic NOS inhibition, oral treatment of Sildenafil reduced
both the arterial blood pressure and peripheral vascular resistance (Ferreira-Melo et al.
2006). In addition, a smaller total area of myocardial lesions and decreased accumulation
of necrotic and fibrotic tissue was observed. cGMP was proposed to be the central
mediator for the anti-cardiomyopathic effects of Sildenafil in these studies.

NF-B: structure and activation
The NF-κB (nuclear factor-kappa B) family of transcription factors is a critical regulator
of various target genes involved in numerous cellular functions, such as apoptosis, cell
proliferation, inflammatory response, nervous system functioning (Malek et al. 2007).
There are five members of the NF-κB family: p50/p105 (NF-κB1), p52/p100 (NF-κB2),
p65 (RelA), RelB, and c-Rel that arrange to form homo- or heterodimers that may be
transcriptionally active or repressive (Ghosh et al. 1998). Transcriptionally inactive
structures are the p50 homodimer and the p52 homodimer, whereas those combinations
that are activators of transcription consist of the p50/p65, p50/c-rel, and p65/c-rel
heterodimers as well as the p65 homodimer (Ghosh et al. 1998). Of the most prominent
and the most relevant to this present study is the p50/p65 dimer.
NF-κB/Rel proteins contain a conserved 300 amino acid rel homology domain
(RHD), shown in figure 5, which happens to be the site of dimerization, DNA binding,
interaction with inhibitory proteins, the IκB family (Ghosh et al. 1998). The Rel proteins
(Rel A RelB, and c-Rel) contain a variable C-terminal transactivation domain. P105 and
p100, respectively the precursors of p50 and p52, contain this region but it is absent in
13

p50 and p52 after post-translation or co-translational processing thorough mechanisms
that are not fully understood (Ghosh et al. 1998; Ghosh and Karin. 2002). It is known
that processing involves the proteolysis of the ankyrin repeats (AR) on p105 and p100,
which occurs constitutively in p105 and in a regulated manner in p100 (Ghosh and Karin.
2002). It should be noted that p50 and p52 repress due to their lack of this transactivation
domain (Ghosh et al. 1998).

Figure 5: Rel/NF-κB and IκB family of proteins. The number of amino acids in each
protein is shown on the right. The arrows point to the C-terminal residues of p50 and p52
(following processing of p105 and p100, respectively). members of the NF-κB family
share the c-Rel homology domain (RHD, rectangle), where as share six to seven ankyrin
repeats (AR, beads) GRR, glycine-rich repeat; IκB, inhibitor of NF-κB; LZ, leucine
zipper; NF-κB, nuclear factor-κB; SS, two conserved serines in IκB (Karin et al. 2004).
14

Proteins of the Rel-family bind specific areas called κB sites on DNA via their
RHD (Ghosh et al. 1998); of interest is the binding of p50/p65 heterodimer.
Dimerization occurs at the C-terminal domains where two identical -sheets interdigitate
(Huang et al. 1997).

The dimer contacts the major groove of DNA via the N-terminal

region of the RHD (Toledano et al. 1993). Taking a closer look, arginines and lysines on
p50 and p65 interact with the guanines of the κB sites. There are a variety of κB sites
specific for the multitude of homo- or heterodimer combinations among the Rel proteins.
These are pentameric sites with a consensus sequence of 5’-GGGRNYYYCC-3’ (R is an
unspecified purine; Y is an unspecified pyrimidine; and N is any nucleotide) (Chen et al.
1998). In particular, the Ig-κB site 5’-GGGACTTTCC-3’, of which the 5-base-pair
subsite GGGAC subsite is bound by p50 and a 4-base-pair subsite TTCC is bound by
p65.
NF-κB is an inducible transcription factor. On receiving an appropriate signal, it
dissociates from IκB and is able to act rapidly without having to synthesize new proteins.
This is the hallmark of NF-κB action which makes it ideal for situations, such as stress
and inflammation, in which the cell has to respond quickly.
In most vertebrate cells, NF-κB is bound to an inhibitor, IκB and held in the
cytoplasm (Ghosh et al. 1998). IκB is a family of inhibitory molecules that includes 7
known mammalian members: IκB, IκB, IκB, IκB, BCL-3 and the pre-cursor Rel
proteins p100 and p105 (Ghosh and Karin. 2002). Docking of the ARs on IκB proteins
to the RHDs of NF-κB proteins achieves the cytoplasmic retention that renders NF-κB
inactive (Karin et al. 2004). In normal quiescent cells, virtually no dissociation of the
15

complex is seen in the absence of stimulation, rendering the IB kinase, IKK, complex
inactive (Karin and Ben-Neriah. 2000). The IKK complex contains two kinase subunits,
IKK and IKK, and a regulatory subunit IKK or NF-κB essential modifier (NEMO).
There are a number ways to activate liberate NF-κB from its inhibitor. The IκB
members interact at their ankyrin repeats with the RHD of NF-κB, such that the nuclear
localization signal (NLS) in the RHD of NF-κB is masked. The most comprehensively
studied pathway for activation is called the classical or canonical pathway for NF-κB
activation. It involves the phosphorylation of IκB on two serine (32 and 36) residues by
IKK due to cell stimulation resulting in the ubquitinization and subsequent proteolysis of
IκBthough theligase transducing repeat containing proteinrCP. Once NFκB is free from IκB, it translocates to the nucleus where it is able to regulate the
transcription of responsive NF-κB genes (Zandi et al. 1997; Yates and Gorecki. 2006).
Some of these target genes are involved in immune response (TNF, IL-1, MCP-1, and
COX2), cell proliferation (cyclin D1, cyclin D2, c-MYC, and JUNB), cell survival (BclXL, Bcl-2, and angiogenesis (VGEF, IL-6 and IL-8).
Recently a non-canonical pathway, involved in B-cell mediated responses and
adaptive humoral immunity has emerged (Karin et al. 2004; Pomerantz and Baltimore.
2002). In this pathway, NF-κB activation is independent of IKK complex but requires
IKK. The scheme of the non-canonical pathway involves the phosphorylation and
subsequent processing of p100/Rel B to p52/Rel B. In this mechanism IKK is activated
by NF-κB inducers such as lymphotoxin- (LT), B-cell activating factor (BAFF),
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receptor activator of NF-κB (RANK), or by the interaction of IKK with NF-κB
inducing kinases (NIK) (Yates and Gorecki. 2006).

NF-B and Apoptosis:
Depending on the stimulus and cell type, NF-κB regulates gene expression of target
genes that can either promote or block apoptosis. It has been shown that the activation of
NF-κB is necessary for p53 mediated apoptotic cell death (Ryan et al. 2000). It has also
been shown that NF-κB is essential in order for Fas (CD95), a cell surface protein, to
induce apoptosis in activated lymphocyte (Chan et al. 1999). Not only does NF-κB have
a crucial role in mediating apoptosis, but it can also promote cell survival. It has been
reported that in tumors, such as breast, melanoma, colon, pancreas, thyroid, and prostate,
NF-κB is essential for tumor development (Nunez et al. 2008). NF-κB can promote
tumor cell survival and growth by inducing genes that encode cyclinD1, which will
phosphorylate Rb leading the cells into S phase of the cell cycle and by upregulating cmyc (Hinz et al. 1999; Karin et al. 2002). Furthermore, NF-κB can also facilitate cancer
progression by activation genes that stimulate angiogenesis and metastases such as
MMP9, uPa, IL-8 and VGEF (Karin et al. 2002).
In many circumstances, NF-B activation mediates chemoresistance by offering
protection from apoptosis (Huang et al. 2000; Wang et al. 1999a; Yamamoto and Gaynor.
2001; Wang et al. 1999b). Therefore, efforts are underway to developing methods to
impinge on this resistance by blocking this aberrant activity. Chemotherapy, tumor
necrosis factor (TNF), and other anticancer stimuli may further activate NF-B, and
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this induction has been reported to play a pivotal role in resistance in vitro by suppressing
the apoptotic potential of these stimuli (Wang et al. 1996; Beg and Baltimore. 1996).

NF-B and Prostate Cancer:
NF-κB modulates the expression of genes for many normal and necessary cell functions;
however in a number of human cancers-especially in prostate cancer, it is aberrantly
activated (Paule et al. 2007). Interestingly, the degree of its activity varies with cancer
cell type with a strong correlation to androgen dependency. For instance, NF-κB activity
is high in androgen-independent cell lines such as PC3 and DU-145 cells, but it is low in
the androgen sensitive cell line LNCaP. With respect to prostate cancer, it appears that
persistent expression of NF-κB is associated with constitutive activation of IKK, which
contributes to increased phosphorylation of IκB. Not much is known about the
signaling pathways that result in IKK activation; however, it appears that activation of
upstream kinases, such as NIK may play a pivotal role (Paule et al. 2007). Nevertheless,
this aberrant activity appears to be problematic in cancer treatment.
One of the most frequent causes of DOX chemotherapy failure is resistance. It
has been demonstrated that the over-expression of anti-apoptotic genes are due to NF-B
activation (Patel et al. 2000). In some cancer cell lines, desensitization to chemotherapy
occurs through the induction in NF-B (Lee et al. 2003). In cardiomyocytes, it appears
that the role of NF-B activation with regard to apoptosis is reversed. It has been shown
that DOX-generated H2O2 induces apoptotic cell death as a result of NF-B activation in
endothelial cells and cardiomyocytes (Wang et al. 2002). It has been reported that H2O2
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modulates the phosphorylation of IKK leading to further degradation of IB(Li et al.
2001). Therefore, inhibition of NF-B activity would be advantageous not only in
sensitizing cells to DOX-induced apoptosis, but also promoting cell survival in
cardiomyocytes.
While effective treatments exist for prostate cancers that are hormone sensitive,
hormone-independent tumors have none. The NO/soluble guanylate cyclase (sGC)
pathway has been reported to be impaired in the androgen-independent cell lines PC3 and
DU145 (Chen et al. 1998), and PDE5 has been shown to be upregulated in human
carcinomas, including prostate cancers (PC3 and LCAP cell lines) (Zhu and Strada.
2007). Moreover, involvement of this PDE5 has been proposed to influence
antiproliferation and caspase-dependent proapoptotic mechanisms in multiple carcinomas
(Zhu et al. 2005; Sarfati et al. 2003).

Goals of the Present Study:
Previous studies from our laboratory assessed the cell viability after treatment
with DOX and Sildenafil in three different cancer cell lines OSA-1, a sarcoma cell line,
UCI-101 and A2780, ovarian cancer cell lines. We observed that Sildenafil enhanced
DOX-induced antiproliferation and apoptosis with an increase in BAX/BCL-2 ratio and
caspase-3. Since DOX is known to activate NF-B in various cancer cells and blocking
NF-B sensitizes cells to DOX-induced apoptosis, we postulated that Sildenafil when
used in combination with DOX would reduce NF-B activation thereby strongly
potentiating apoptosis in PC3 cells. Specifically, we investigated the combined effect of
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DOX and Sildenafil in attenuating the activation of NF-B. We studied the effect of
Sildenafil plus DOX on inhibition of translocation of p65 and p50 subunits to the
nucleus, phosphorylation of cytosolic IB and its resultant influence on apoptosis. In
addition, we investigated the effect of DOX and DOX plus Sildenafil on the expression
of BCL family of proteins which play critical role in apoptosis. The studies were carried
out in vitro in PC-3 cell line.
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Material and Methods

Materials:
DOX was obtained from Sigma Chemical Co. PS (Pen-Strep) was obtained from
Invitrogen. F-12K Medium was obtained from ATCC (American Type Cell Collection).
Cell titer96@AQueous one solution cell proliferation assay kit and 5X Reporter Lysis
Buffer were obtained from Promega Co. FBS (Fetal Bovine Serum) was purchased from
Gemini Bioproduct. Bad, pBad (Ser112), BCLxL, IB, pIB (Ser32), p65, p50, tubulin, and actin antibodies were purchased from SantaCruz Biotechnology. NF-B
Transfactor extraction kit was obtained from Clontech (631930 and 631921). Sildenafil
was kindly provided by Pfizer Inc. Secondary antibodies (anti-mouse, anti-rabbit, and
anti-goat) were purchased from Amersham Biosciences. ECL western blotting detecting
reagents were purchased from GE Healthcare. SuperSignal West Femto Maximum
Sensitivity Substrate was obtained from Pierce.

Cell Culture:
PC-3 cells were obtained from the American Type Cell Collection. Cells were grown in
F-12K medium containing 10% FBS and 1% PS at 37°C in a humidified incubator with
5% CO2 and 95% O2.
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Cell Viability Assay:
Cells (Approximately 15,000 cells/well) were plated on 96 wells plate 24 hours before
the treatments. Cells were treated with 1.5µM of DOX and /or 10µM of Sildenafil for 72
hours. Cell viability was assessed using Cell titer96@AQueous one solution cell
proliferation assay kit. Plates were read at the absorbance of 590 nM.

Western Blot:
For NF-BandB, nuclear extractions were prepared using Clontech Extraction Kit
isolated from cells after 6 hours of treatment. Protein was run on a 10% gel for NF-B
and 12.5% gel for B. To measure pBad, Bad, BCLxL, total soluble protein was
extracted from the cells using Reporter Lysis Buffer (Promega) by a repeated freeze and
thaw method. Protein (total soluble, cytoplasmic, or nuclear) was estimated by Bradford
assay using Bio-Rad protein assay kit. For NF-B, 30 g of protein from each sample
was separated by 10% SDS-PAGE Criterion Precast Gel and 150 g of protein was run in
a 12.5% gel for pB and B. For pBad, Bad, BCLxL, 150 g of protein was
separated on a 15% gel. Gels were run at 165V for 1.5 hours with TGS buffer TrisGlycine-SDS). The proteins were transferred onto nitrocellulose membrane for 1.5 hours
at 400 AMPS at 4oC with TG buffer (Tris-Glycine). The blot was incubated with 5%
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nonfat dry milk in TBST (10mM Tris-HCL, pH 7.4, 10mM NaCl, and 0.1% Tween 20)
for 1 hour. Thereafter, the blot was incubated with rabbit polyclonal primary antibodies
for BCLxL, pBad, pIB, p65, p50; mouse monoclonal antibodies for IB and Bad; and
goat polyclonal primary antibody of -tubulin and actin at a dilution of 1:1000 for tubulin and actin, 1:250 for BCLxL, pBad and pIB, and 1:500 for p65, p50 in 5%
nonfat dry milk in TBST for overnight at 4oC. The membranes were washed three times
with TBST at RT. The membranes were then incubated with anti-rabbit, anti-mouse, or
anti-goat horseradish peroxidase-conjugated secondary antibody at a dilution of 1:2000
(1:1000 for BCLxL, pBAD, BAD, pIB, and IBfor 1 hour. The membranes were
washed again and then developed using an ECLTM Western blot detection reagents and
exposed to X-ray film. SuperSignal West Femto Maximum Sensitivity Substrate was
used to develop BCLxL, pBAD, BAD, pIB, and IB. The bands were scanned and
quantified by densitometric analysis (Image J).

Statistical analysis and densitometry. To quantitate differences in images of protein
expression, films were scanned and densitometry performed using NIH Image 1.73V
software. For all statistical comparisons, GraphPad Prism software (Version 4.03) was
used. For multiple comparisons, analysis of variance using Newman-Keuls post test. p <
0.05 was considered to be statistically significant.
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Results
Perspective
Previously, we have shown by a Cell Viability Assay that Sildenafil enhances DOXinduced killing of PC3 cells. Figure 6 shows a 43% decrease in cell viability following
72 treatment of 1.5 μM DOX and 10μM Sildenafil compared with DOX alone.
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Figure 6: Cell Viability Assay after 72 hrs of treatment of PC3 cells with 1.5M DOX
and 10M Sildenafil (Sil); n = 6; means ± S.E., one-way ANOVA, Newman-Keuls post
test. P < 0.001 vs. Control P < 0.001 vs. DOX
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This encouraged us to investigate the rationale behind Sildenafil action on Doxorubicininduced apoptosis. Since DOX is known to activate NF-B in diverse cancer cells, it was
of interest to determine whether Sildenafil co-administration along with DOX treatment
is augmenting cell death through the inhibition of NF-B.
DOX showed a significant induction NF-B in the nuclear translocation of both
the p65 and p50 subunits of PC3 cells treated for 6 hours with 1.5μM DOX and 10µM
Sildenafil compared to the control (figures 7 and 8). It was found that combination
treatment of DOX and Sildenafil significantly reduced the nuclear translocation of p65 as
compared with DOX alone by 45% (P < 0.05) and p50 by 37% (P < 0.05). The decline
of NF-B was supported by the western blot for p-IB, which showed a trend in the
increase of the ratio of p-IB / IBcompared to the control. The phosphorylation of
IB was reduced even further with DOX/ Sildenafil combination treatment as compared
to DOX administration alone (figure 9).
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Figure 7: Nuclear translocation of the p65 subunit of NF-B in PC3 cells after 6 hrs
treatment with 1.5M DOX and 10M Sildenafil (Sil). A: Western blot. B:
Densitometric depiction. P < 0.05 vs. DOX and *P < 0.01 vs. Control. n = 4; means ±
S.E., one-way ANOVA, Newman-Keuls post test.
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Figure 8: Nuclear translocation of the p50 subunit of NF-B in PC3 cells after 6 hrs
treatment with 1.5M DOX and 10M Sildenafil (Sil) A: Western blot. B: Densitometric
depiction. n = 4; means ± S.E., one-way ANOVA, Newman-Keuls post test. P < 0.05
vs. DOX and *P < 0.05 vs. Control.
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Figure 9: p-IB protein levels in PC3 cells after 6 hrs treatment with 1.5M DOX and
10M Sildenafil (Sil). A: Western blot. B: Densitometric depiction. n = 4; means ± S.E.,
one-way ANOVA, Newman-Keuls post test.
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Apoptotic Indexes:
Since NF-B is has been shown to play a pivotal role in the regulation of cellular
growth and apoptosis, we looked at the expression of proteins that are suppressors of
apoptosis and those that inducers of apoptosis (Beg and Baltimore. 1996; Wang et al.
1998a). For these studies, PC3 cells were harvested 72 hours after drug treatments. We
observed a 52% (P < 0.001) reduction in BCL-2 protein levels was observed with DOX
alone. Treatment of Sildenafil in combination with DOX reduced the densitometric ratio
of BCL-2 /-tubulin further from 0.449 ± 0.013 (DOX alone) to 0.329 ± 0.035 (P <
0.05) (figure 10). DOX treatment alone had an overall trend of higher levels of BCLxL as
compared with control (figure 11). Sildenafil co-treatment with DOX significantly
reduced BCLxL protein levels by 33% (P < 0.05). Phosphorylation of BAD (pBAD) was
significantly reduced by 26% (P < 0.05) in DOX treated PC3 cells as compared to the
control (figure 12). Treatment of Sildenafil in combination with DOX reduced the
densitometric ratio of pBAD /D further augmented the reduction in the BAD
phosphorylation from 0.609 ± 0.089 to 0.341 ± 0.043 (P < 0.05).
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Figure 10: BCL-2 levels in PC3 cells after 6 hrs treatment with 1.5M DOX and 10M
Sildenafil (Sil). A: Western blot. B: Densitometric depiction. n = 4; means ± S.E., oneway ANOVA, Newman-Keuls post test. P < 0.05 vs. DOX and *P < 0.001 vs. Control
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Figure 11: BCLxL protein levels in PC3 cells after 6 hrs treatment with 1.5M DOX and
10M Sildenafil (Sil). A: Western blot. B: Densitometric depiction n = 4; means ± S.E.,
one-way ANOVA, Newman-Keuls post test. P < 0.05 vs. DOX.
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Figure 12: pBad levels in PC3 cells after 6 hrs treatment with 1.5M DOX and 10M
Sildenafil (Sil). A: Western blot. B: Densitometric depiction. n = 4; means ± S.E., oneway ANOVA, Newman-Keuls post test. P < 0.05 vs. DOX and *P < 0.05 vs. Control.
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Discussion
Perspective
Prostate cancer can be treated by androgen ablation, because the solid tumors are androgendependent. However, PC frequently progresses to a lethal, androgen-independent form,
AIPC, which has limited treatment options.

Several studies have shown that PDE-5 inhibitors precondition the heart against
I/R in vivo and in vitro (Das et al. 2005; Ockaili et al. 2002; Das et al. 2004; Salloum et
al. 2003; Bremer et al. 2005; Salloum et al. 2007; Salloum et al. 2008). The PDE-5
inhibitor, Sildenafil preconditions the heart against I/R through the generation of NO by
activation of eNOS and iNOS, activation of PKC, and opening of the mitochondrial KATP
channels (Das et al. 2005; Ockaili et al. 2002; Das et al. 2004; Salloum et al. 2003).
Sildenafil can also offer protection against apoptosis and necrosis through a NOSdependent upregulation of BCL-2/Bax in cardiomyocytes (Das et al. 2005). Moreover,
recent studies from our lab have shown that Sildenafil protects the heart and
cardiomyocytes against I/R injury through a novel signaling cascade involving protein
kinase G (PKG)-dependent activation of ERK and inhibition of glycogen synthase kinase
3β (Das et al. 2008). Sildenafil also inhibits DOX-induced cardiomyocyte apoptosis by
preventing the loss ofm, caspase-3 activation, and increasing the levels of BCL-2
(Fisher et al. 2005).
33

In addition to the above cited studies on the cardioprotective effect of PDE-5 inhibitors,
unpublished studies from our laboratory have provided a powerful evidence that
Sildenafil in combination with DOX significantly decreased cell viability in several
cancer cell lines including sarcoma (OSA-1), ovarian (UCI-101 and A2780) and prostate
(PC-3) (see figure 6). Similar combination of DOX plus Sildenafil decreased the size of
tumor in ovarian cancer xenograft model (Kukreja RC et al. 2008). Moreover, Sildenafil
treatment caused higher distribution of DOX in the tumors which is a favorable
pharmacokinetic feature for improving the efficacy of DOX.
Since DOX is known to activate NF-B in various cancer cells and blocking NFB sensitizes cells to DOX-induced apoptosis, we hypothesized that Sildenafil when used
in combination with DOX would attenuate NF-B activation that may lead to
potentiation of apoptosis in PC3 cells. Accordingly we carried out experiments to study
the combined effect of DOX and Sildenafil in attenuating the activation of NF-B by
measuring the translocation of p65 and p50 subunits to the nucleus, phosphorylation of
cytosolic IB and its resultant influence on apoptosis. In addition, we investigated the
effect of DOX and DOX plus Sildenafil on the expression of BCL family of proteins
which play critical role in apoptosis. Our results show that the combined treatment of
DOX and Sildenafil significantly reduced the nuclear translocation of p65 and p50 as
compared with DOX. This correlated with a reduction in the phosphorylation of the
expression of BCL2, BCLxL and pBAD. Our results suggest that Sildenafil treatment
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augments the apoptotic potential of DOX by decreasing NF-B activation in PC3 cancer
cells.
NF-B is a pleiotropic nuclear transcription factor that controls the expression of
a myriad of genes involved in immunity, inflammation, and carcinogenesis (Wulczyn et
al. 1996; Barnes and Karin. 1997). NF-B is inhibited by IB family of proteins which
are susceptible to phosphorylation by IKKs following the appropriate stimulus.
However, in some cancer cells, NF-B is known to be constitutively activated which has
been associated with low IB- expression and high IB- degradation (Bargou et al.
1996). Depending on the circumstance, is capable of promoting apoptosis or promoting
cell survival. In cancer cells, it generally appears that constitutive NF-κB activation is in
favor of cell survival.
Indeed, it is well established that DOX and other anthracyclines induce NF-B
activation (Bian et al. 2001). Since this induction of NF-B may confer resistance in
cancer, many studies have taken effort to inhibit NF-B activation. For example, it was
demonstrated that soy isoflavone pre-treatment inactivates NF-B and may contribute to
increased growth inhibition and apoptosis by Cisplatin, Docetaxel, and Doxorubicin in
prostate, breast, lung, and pancreatic cancer cells (Li and Wogan. 2005). Therefore it
was of interest to determine whether the PDE5 inhibitor, Sildenafil will block the
induction of NF-B and whether this inhibition will potentiate apoptosis. Our results
demonstrate that Sildenafil in combination with DOX does significantly reduce the
nuclear translocation of the p65 and p50 of NF-B subunits as compared to cells that are

35

treated with DOX alone (figures 7 and 8). IBsequesters NF-B in the cytosol by
masking itsNLS. This inhibition is removed by phosphorylation and subsequent
degradation of IB by IKK. We observed an overall increase in the reduction in pIBfollowing DOX treatment and a reduction in the levels of p- IB following
combination treatment of DOX plus Sildenafil. The results for p- IB; however, were
not statistically significant.
While it is known that NF-B is constitutively expressed in androgen-independent
PC3 cells; here we show that DOX serves to further augment NF-B levels as
demonstrated with the upregulation in p50, 65, as well as p-IB following DOX
treatment. Sildenafil appears might be chemosensitizing PC3 cells to DOX
chemotherapy by modulating the activity of NF-κB.

NF-B - Apoptosis Connection:
Since NF-B is known to promote anti-apoptotic proteins in cancer cells by
upregulating an array of survival genes, we therefore assessed the expression of BCL
family of proteins, particularly the BCL-2 and BCLxL and phosphorylated BAD.

Our

goal was to show whether this induction of NF-B in PC3 cells as a result of DOX
treatment would enhance survival mechanism and whether we can diminish these levels
using combination treatment with Sildenafil plus DOX. We found that DOX treatment
alone had the higher levels of BCLxL as compared with control in PC3 cells (figure 11).
These data suggest a possible connection of NF-B with the regulation of apoptosis in

36

PC3 cells. In this respect, it appears that the induction of NF-B in PC3 cells is favoring
cell survival evidenced by the increase in BCLxL protein levels. However, co-treatment
of Sildenafil with DOX significantly reduced BCLxL as compared with DOX alone. This
implies that Sildenafil is undermining PC3 cell survival and sensitizing them to DOX
chemotherapy.
It is of interest to examine the phosphorylation of BAD and its relation to BCL-2
and BCLxL. BAD is a pro-apoptotic protein that interacts with cell survival proteins, such
as BCL-2 and BCLxL to inhibit them. This ultimately leads to cell death by opening
mitochondrial permeability transition pore, encouraging the release of cytochrome c and
activation of the apoptosome. This death agonist is regulated by kinases that
phosphorylate BAD on at least one of two serine residues, Ser112 or Ser136 by cAMPdependent protein kinase (PKA) or protein kinase B (PKB; also known as Akt)
respectively (Bonni et al. 1999; Datta et al. 1997) in response to survival-promoting
factors, such as nerve growth factor, insulin-like growth factor-1, and interleukin-3 (IL-3)
(Zha et al. 1996; Datta et al. 1997; Yang et al. 1995). In the present study, we observed a
significant decrease in the ratio of pBAD/BAD with DOX, and a further decline in these
levels by co-treatment with Sildenafil plus DOX (figure 12). This decrease in
pBAD/BAD ratio indicates DOX is activating BAD facilitating the removal of the
inhibition so that it may function as a death agonist and potentially inhibit the cell
promoting BCL-2 family proteins. According to our results, this is in accordance with
BCL-2 but not for BCLxL. Co-administration of Sildenafil along with DOX significantly
reduced both of the survival proteins, BCL-2 and BCLxL, which is in agreement with
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reduced BAD phosphorylation favoring apoptosis. These findings demonstrate that
combined treatment with Sildenafil along with DOX is further potentiating the apoptotic
effect of DOX.
Apoptosis has been shown to be induced by NO in a concentration-dependent
manner by activating caspase-3(Lin et al. 1998). NO has the ability to potentiate
apoptosis in various cell types through mechanisms that involve p53 accumulation, poly
(ADP ribose) polymerase (PARP) induction, and BCL-2 down-regulation (Li and
Wogan. 2005; Umansky et al. 2001; Li et al. 2006). Interestingly, NO has been shown to
restrain the DNA binding of activity of NF-κB (Matthews et al. 1996). It is conceivable
that NO may potentiate apoptosis by modulating NF-κB. Thus, Sildenafil activation of
nitric oxide synthase may be responsible for the reduction in the nuclear translocation of
the p65/50 dimer. Thus, Sildenafil co-administration appears to be potentiating the
therapeutic efficacy of DOX by inhibiting NF-κB.

Future Directions
PDE-5 is found to be upregulated in prostate cancer (LNCAP and PC3), and ED
is encountered following all forms prostate cancer therapy (Rambhatla et al. 2008).
Sildenafil not only serves to treat ED but also may increase the efficacy of DOX as a
chemotherapeutic agent as suggested by the studies from our laboratory. Therefore, it
would be more advantageous to use Sildenafil during anti-oncogenic therapies to
potentiate cancer cell death and protect against cardiotoxicity rather than utilize it for the
sole purpose to treating ED post cancer therapy.
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Clinicians generally employ multiple chemotherapeutic agents in order to gain
better treatment outcome; however, this leads to systemic cytotoxicity which often results
in detrimental side effects (Daniels et al. 2006). Therefore, utilizing a nonchemotherapeutic drug along with a chemotherapeutic agent would achieve targeted
inactivation of NF-B, which may lead to more DOX-induced apoptosis of cancer cells
without the harmful side-effects. Since Sildenafil has been in clinical use for over ten
years, its co-treatment with a chemotherapeutic agent, such as DOX may potentiate the
destruction of malignant cells and tissues without further contribution of toxicity of noncancerous tissues.
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